End the duopoly

MedPAC finds 340B effect on pricing ‘modest,’ going against pharma critique

0 10

Get real time updates directly on you device, subscribe now.

Credit: McKnight Dive Brief: A Medicare Payment Advisory Commission study found spending on cancer drugs at hospitals participating in the 340B drug discount program was only 2% to 5% higher than non-340B hospitals and 1% to 7% higher than physician offices. The overall effect of the controversial program on cost-sharing for patients is "likely to be small, if any," the Congressional advisory group said. Researchers were careful to point out they couldn’t directly attribute […]

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More